Ocular Inflammation - Pipeline Review - H1 2014





Published: April 2014 | Pages: 98 | Format: PDF

Summary

Global Markets Direct’s, ‘Ocular Inflammation - Pipeline Review, H1 2014’, provides an overview of the Ocular Inflammation’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ocular Inflammation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ocular Inflammation and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Ocular Inflammation
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Ocular Inflammation and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Ocular Inflammation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Ocular Inflammation pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Ocular Inflammation
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Ocular Inflammation pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 

Table of Contents

Introduction 8
Global Markets Direct Report Coverage 8
Ocular Inflammation Overview 9
Therapeutics Development 10
Pipeline Products for Ocular Inflammation - Overview 10
Pipeline Products for Ocular Inflammation - Comparative Analysis 11
Ocular Inflammation - Therapeutics under Development by Companies 12
Ocular Inflammation - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Ocular Inflammation - Products under Development by Companies 18
Ocular Inflammation - Companies Involved in Therapeutics Development 20
UMeWorld Limited 20
Sun Pharmaceutical Industries Limited 21
Bayer AG 22
InSite Vision Incorporated 23
Reata Pharmaceuticals, Inc. 24
Xigen SA 25
Enceladus Pharmaceuticals BV 26
SIFI S.p.A 27
Celsus Therapeutics Plc 28
Auven Therapeutics Management L.L.L.P 29
Cancer Therapeutics CRC Pty Ltd 30
Kala Pharmaceuticals, Inc. 31
Icon Bioscience, Inc. 32
Ocular Therapeutix, Inc. 33
Panmira Pharmaceuticals, LLC. 34
Clearside BioMedical, Inc. 35
Neuroptis Biotech 36
Ocular Inflammation - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Target 38
Assessment by Mechanism of Action 41
Assessment by Route of Administration 44
Assessment by Molecule Type 46
Drug Profiles 48
bromfenac sodium - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
dexamethasone acetate - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
dexamethasone - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
mapracorat - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
dexamethasone acetate SR - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
XG-102 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
RX-10045 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
loteprednol etabonate - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
RTA-408 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
triamcinolone acetonide - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
ketorolac tromethamine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
AM-679 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
SF-110 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
SF-111 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OPX-1 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ARX-8203 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
NOP-5 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Sun-0597 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
LIMK1 AND LIMK2 Inhibitors - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
SF-101 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Liposomal corticosteroid - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
prednisolone - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Ocular Inflammation - Recent Pipeline Updates 76
Ocular Inflammation - Dormant Projects 87
Ocular Inflammation - Discontinued Products 88
Ocular Inflammation - Product Development Milestones 89
Featured News & Press Releases 89
Mar 17, 2014: Ocular Therapeutix Begins Phase 3 Clinical Trial for its Sustained Release Dexamethasone 89
Nov 12, 2013: Kala Pharmaceuticals Presents Preclinical Data on Mucus Penetrating Particles at 2013 AAPS Annual Meeting and Exposition 89
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 90
Oct 01, 2013: Ocular Therapeutix Announces Phase 2 Study Results for Sustained Release Dexamethasone 90
Sep 24, 2013: Eleven Biotherapeutics to Present at the Targeting Ocular Disorders Conference 91
Jun 03, 2013: Ocular Therapeutix Completes Enrollment In Phase II Study For Sustained Release Dexamethasone 91
May 24, 2013: Ista Pharma To Pay $33.5m To Resolve Criminal Liability And False Claims Act Allegations 92
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 94
May 08, 2013: Eleven Biotherapeutics Presents Clinical Data On EBI-005 At ARVO 2013 Annual Meeting 94
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision's Bromsite 96
Appendix 97
Methodology 97
Coverage 97
Secondary Research 97
Primary Research 97
Expert Panel Validation 97
Contact Us 98
Disclaimer 98

List of Tables

Number of Products under Development for Ocular Inflammation, H1 2014 10
Number of Products under Development for Ocular Inflammation - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Comparative Analysis by Late Stage Development, H1 2014 15
Comparative Analysis by Clinical Stage Development, H1 2014 16
Comparative Analysis by Early Stage Development, H1 2014 17
Products under Development by Companies, H1 2014 18
Products under Development by Companies, H1 2014 (Contd..1) 19
Ocular Inflammation - Pipeline by UMeWorld Limited, H1 2014 20
Ocular Inflammation - Pipeline by Sun Pharmaceutical Industries Limited, H1 2014 21
Ocular Inflammation - Pipeline by Bayer AG, H1 2014 22
Ocular Inflammation - Pipeline by InSite Vision Incorporated, H1 2014 23
Ocular Inflammation - Pipeline by Reata Pharmaceuticals, Inc., H1 2014 24
Ocular Inflammation - Pipeline by Xigen SA, H1 2014 25
Ocular Inflammation - Pipeline by Enceladus Pharmaceuticals BV, H1 2014 26
Ocular Inflammation - Pipeline by SIFI S.p.A, H1 2014 27
Ocular Inflammation - Pipeline by Celsus Therapeutics Plc, H1 2014 28
Ocular Inflammation - Pipeline by Auven Therapeutics Management L.L.L.P, H1 2014 29
Ocular Inflammation - Pipeline by Cancer Therapeutics CRC Pty Ltd, H1 2014 30
Ocular Inflammation - Pipeline by Kala Pharmaceuticals, Inc., H1 2014 31
Ocular Inflammation - Pipeline by Icon Bioscience, Inc., H1 2014 32
Ocular Inflammation - Pipeline by Ocular Therapeutix, Inc., H1 2014 33
Ocular Inflammation - Pipeline by Panmira Pharmaceuticals, LLC., H1 2014 34
Ocular Inflammation - Pipeline by Clearside BioMedical, Inc., H1 2014 35
Ocular Inflammation - Pipeline by Neuroptis Biotech, H1 2014 36
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Stage and Target, H1 2014 40
Number of Products by Stage and Mechanism of Action, H1 2014 43
Number of Products by Stage and Route of Administration, H1 2014 45
Number of Products by Stage and Molecule Type, H1 2014 47
Ocular Inflammation Therapeutics - Recent Pipeline Updates, H1 2014 76
Ocular Inflammation - Dormant Projects, H1 2014 87
Ocular Inflammation - Discontinued Products, H1 2014 88

List of Figures

Number of Products under Development for Ocular Inflammation, H1 2014 10
Number of Products under Development for Ocular Inflammation - Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Early Stage Products, H1 2014 17
Assessment by Monotherapy Products, H1 2014 37
Number of Products by Top 10 Target, H1 2014 38
Number of Products by Stage and Top 10 Target, H1 2014 39
Number of Products by Top 10 Mechanism of Action, H1 2014 41
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 42
Number of Products by Top 10 Route of Administration, H1 2014 44
Number of Products by Stage and Top 10 Route of Administration, H1 2014 45
Number of Products by Top 10 Molecule Type, H1 2014 46
Number of Products by Stage and Top 10 Molecule Type, H1 2014 47